Business
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.\n\n\nThe conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.\n\n\nAbout Acadia Pharmaceuticals\n\n\nAcadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240313546332/en/\n\nInvestor Contact:\nAcadia Pharmaceuticals Inc.\nAl Kildani\n(858) 261-2872\[email protected]\n\n\nAcadia Pharmaceuticals Inc.\nJessica Tieszen\n(858) 261-2950\[email protected]\n\n\nSource: Acadia Pharmaceuticals Inc.","length":3664,"tagName":"div"}]